HYBIO(SZ:300199) Xin Lang Cai Jing·2025-09-26 02:02Group 1 - The core point of the news is that Hanyu Pharmaceutical experienced a decline of 5.02% in its stock price, reaching 21.96 CNY per share, with a trading volume of 459 million CNY and a turnover rate of 2.78%, resulting in a total market capitalization of 19.396 billion CNY [1] - Hanyu Pharmaceutical, established on April 2, 2003, and listed on April 7, 2011, is located in the Guanlan High-tech Park, Longhua District, Shenzhen, Guangdong Province. The company primarily engages in chemical pharmaceuticals and medical devices, with 100% of its revenue derived from the pharmaceutical manufacturing sector [1] Group 2 - From the perspective of major fund holdings, one fund under China Merchants Fund has a significant position in Hanyu Pharmaceutical. The fund, named China Merchants Stable Growth Mixed A (010503), reduced its holdings by 500 shares in the second quarter, maintaining a total of 500 shares, which accounts for 0.02% of the fund's net value, ranking as the ninth largest holding [2] - The China Merchants Stable Growth Mixed A fund was established on February 5, 2021, with a latest scale of 23.4958 million CNY. Year-to-date, it has achieved a return of 1.46%, ranking 7623 out of 8171 in its category, while its one-year return is 3.14%, ranking 7659 out of 8004 [2] - The fund manager, Chen Jiarong, has a tenure of 16 years and 282 days, with the total asset scale of the fund currently at 50.5506 million CNY. During his tenure, the best fund return was 45.74%, while the worst was -4.97% [2]